But the study did not demonstrate a statistically significant prolongation of overall survival, a secondary endpoint, for either dose in combination with gemcitabine and cisplatin chemotherapy compared to chemotherapy alone.
Median survival of patients in all arms of the study exceeded one year, longer than previously reported survival times in this indication. No new safety signals for Avastin were observed in the study, and there were no clinically meaningful differences in safety between the two doses of Avastin.
Hal Barron, senior vice president, development and chief medical officer, Genentech, said: “These studies reinforce our belief that Avastin is an important treatment option for patients with this most common form of lung cancer.”